The cost effectiveness of prenatal ultrasound screening for trisomy 21

International Journal of Technology Assessment in Health Care

Volumn 20, Issue 4, 2004, Pages 464-468

  Harris, Anthony H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cost effectiveness; Prenatal screening; Ultrasound

Indexed keywords

COST EFFECTIVENESS; DIAGNOSIS; HEALTH CARE; HEALTH RISKS; HOSPITALS; PATIENT MONITORING; PUBLIC POLICY; ULTRASONIC IMAGING;

NUCHAL TRANSLUCENCY SCREENING; PREGNANCY; TRISOMY; ULTRASOUND SCREENING;

DISEASES;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; FETUS; FETUS ECHOGRAPHY; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HEALTH CARE COST; HUMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; REVIEW; SECOND TRIMESTER PREGNANCY; SEROLOGY; TRISOMY 21;

EID: 8544246486     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462304001369     Document Type: Review

References (11)

1. Cheffins T, Chan A, Haan EA, et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. Br J Obstet Gynaecol. 2000;107:1453-1459.
2. Cuckle HS, Wald NJ. Screening for Downs syndrome. In: Lilford R, ed. Prenatal diagnosis and prognosis. London: Butterworths; 1990:67-89.
3. Gilbert RE, Augood C, Gupta R, et al. Screening for Down's syndrome: Effects, safety, and cost effectiveness of first and second trimester strategies. BMJ. 2001;322:423-436.
4. Medical Services Advisory Committee 2003. Nuchal translucency measurement in the first trimester of pregnancy for the screening of trisomy 21 and other autosomal trisomies. May 2002 MSAC reference 4 Assessment report. Canberra: Commonwealth of Australia.
5. Mooney G, Lange M. Ante-natal screening: What constitutes 'benefit'? Soc Sci Med. 1993;37:873-878.
6. SABDR (South Australian Birth Defects Register) 1997. Annual report of the South Australian Birth Defects Register. Adelaide: SABDR; 1998.
7. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet. 1998;352:343-346.
8. Snijders RJ, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther. 1995;10:356-367.
9. Vintzileos AM, Ananth CV, Smulian JC, et al. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol. 2000;95:577-583.
10. Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen. 1997;4:181-246.
11. Yates JM, Lumley J, Bell RJ. The prevalence and timing of obstetric ultrasound in Victoria 1991-1992: A population-based study. Aust N Z J Obstet Gynaecol. 1995;35:375-379.